## *In vitro* maturation alters gene expression in bovine oocytes

*Paulo R. Adona*<sup>1,2,4</sup>, *Cláudia L.V. Leal*<sup>4</sup>, *Fernando H. Biase*<sup>5</sup>, *Tiago H. De Bem*<sup>4</sup>, *Lígia G. Mesquita*<sup>4</sup>, *Flávio V. Meirelles*<sup>4</sup>, *André L. Ferraz*<sup>6</sup>, *Luiz R. Furlan*<sup>7</sup>, *Paulo S. Monzani*<sup>2,3</sup> *and Samuel Guemra*<sup>2,3</sup> Universidade Norte do Paraná, Arapongas, Brazil; Agropecuária Laffranchi, Tamarana, Brazil; Universidade de São Paulo, Pirassununga, Brazil; Auburn University, USA; Universidade estadual de Mato Grosso do Sul, Aquidauana, Brazil; and Universidade Estadual Paulista, Botucatu, Brazil

Date submitted: 12.02.2015. Date revised: 20.10.2015. Date accepted: 29.10.2015

### Summary

Gene expression profiling of *in vivo*- and *in vitro*-matured bovine oocytes can identify transcripts related to the developmental potential of oocytes. Nonetheless, the effects of *in vitro* culturing oocytes are yet to be fully understood. We tested the effects of *in vitro* maturation on the transcript profile of oocytes collected from *Bos taurus indicus* cows. We quantified the expression of 1488 genes in *in vivo*- and *in vitro*-matured oocytes. Of these, 51 genes were up-regulated, whereas 56 were down-regulated ( $\geq$ 2-fold) in *in vivo*-matured oocytes in comparison with *in vitro*-matured oocytes. Quantitative real-time polymerase chain reaction (PCR) of nine genes confirmed the microarray results of differential expression between *in vivo*- and *in vitro*-matured oocytes (*EZR, EPN1, PSEN2, FST, IGFBP3, RBBP4, STAT3, FDPS* and *IRS1*). We interrogated the results for enrichment of Gene Ontology categories and overlap with protein–protein interactions. The results revealed that the genes altered by *in vitro* maturation are mostly related to the regulatory networks affected by the *in vitro* culture system. We propose that the differentially expressed genes are candidates for biomarkers of oocyte competence. *In vitro* oocyte maturation can affect the abundance of specific transcripts and are likely to deplete the developmental competence.

## Introduction

Cumulus–oocyte complexes (COCs) are dependent on adequate gene expression to initiate and to undergo oocyte maturation (meiotic progression) and embryonic development (Labrecque *et al.*, 2013; Li *et al.*, 2013). The mechanisms by which oocytes acquire competence to develop up to the blastocyst stage are still not fully understood. There is evidence that the acquisition of competence is correlated with RNA and protein molecules processed and stored during growth and maturation periods (Ferreira *et al.*, 2009; Caixeta *et al.*, 2013). To enable the storage and the convenient use of the molecules stored in oocytes, several mechanisms should act efficiently (Gandolfi & Gandolfi, 2001; Tomek *et al.*, 2002). Some transcripts have already been associated with oocyte developmental competence (Caixeta *et al.*, 2009; Katz-Jaffe *et al.*, 2009; Biase *et al.*, 2010; Kanka *et al.*, 2012; Bessa *et al.*, 2013; Biase *et al.*, 2014), and those results support the hypothesis that specific RNAs or proteins produced during oogenesis contribute to oocyte competence (Sirard *et al.*, 2006).

It is estimated that during embryogenesis about 5000–10,000 genes are simultaneously expressed in occytes with a high level of control (Niemann *et al.*, 2007). The transcripts for key transcription factors represent a small number of copies and the ones that encode most of the structural proteins may represent approximately 2% of the mRNA pool (Yu *et al.*, 2002). Approximately 10–20% of total RNA consists of

<sup>&</sup>lt;sup>1</sup>All correspondence to: Paulo R. Adona. Agropecuária Laffranchi. PO box 45. Zip Code: 86125-000 – Tamarana, Paraná. Brazil. Tel: +55 43 33994700. E-mail: paulo\_adona@yahoo.com.br

<sup>&</sup>lt;sup>2</sup>Escola de Medicina Veterinária, Universidade Norte do Paraná, Arapongas, PR, Brazil.

<sup>&</sup>lt;sup>3</sup>Laboratório de Reprodução Animal, Agropecuária Laffranchi, Tamarana, PR, Brazil.

<sup>&</sup>lt;sup>4</sup>Departamento de Ciências Básicas, Universidade de São Paulo, Pirassununga, SP, Brazil.

<sup>&</sup>lt;sup>5</sup>Department of Animal Sciences, Auburn University, Auburn, AL, USA.

<sup>&</sup>lt;sup>6</sup>Escola de Zootecnia, Universidade estadual de Mato Grosso do Sul, Aquidauana, MS, Brazil.

<sup>&</sup>lt;sup>7</sup>Departamento de Tecnologia, Universidade Estadual Paulista, Botucatu, SP, Brazil.

The molecular mechanisms that govern oocyte competence are mostly still unknown. However, some oocyte-specific genes have been described revealing their importance in promoting embryogenesis (Katz-Jaffe et al., 2009; Biase et al., 2010; Belli et al., 2013; Bessa et al., 2013; Biase et al., 2014). The profiling of gene expression in oocytes during maturation may help us understand the regulation of oocyte competence to mature and to sustain embryo development during the first two cleavages (Fair et al., 2007). It also promotes the identification of molecular markers for oocyte developmental potential. Nonetheless, most studies have addressed this subject in taurine subspecies (Bos *taurus taurus*). Here, we performed microarray-based transcriptome analyses of in vivo- and in vitro-matured bovine oocytes collected from *Bos taurus indicus* cows in order to enrich our knowledge of genes involved in the acquisition of oocyte competence.

## Materials and methods

## Estrous synchronization and superovulation protocols

Eight Nelore cows (crossbred) with good body condition and in reproductive age were synchronized on random days of the estrous cycle (D0) by intramuscular (IM) application of 2 mg estradiol benzoate RIC-BE (Tecnopec) and with placement of a bovine intravaginal progesterone device (Schering) for 8 days. On the fourth day (D4) follicle-stimulating hormone (FSH) treatment (Follitropin-V, Vetrepharm) was initiated with decreasing doses (80, 60, 40 or 20 mg FSH – IM) during 4 consecutive days. Simultaneously with the last FSH application (D7), cows received 0.150 mg Prolise (D-cloprostenol, IM), a PGF<sub>2α</sub> analogue (Tecnopec), and after 36 h (D8), the animals were separated randomly into two groups of four animals for oocyte collection.

One group (n = 4) was designated for collection of immature oocytes at the germinal vesicle stage (GV). The intravaginal progesterone device was removed from the cows at D8 and oocyte collection was performed by ultrasound-guided follicular aspiration ovum pick up (OPU) so that they could be matured *in vitro*.

The second group (n = 4) was designated for collection of *in vivo*-matured (MII) oocytes. The intravaginal progesterone device was removed from the cows at D8, 25 mg luteinizing hormone (LH) (Lutropin-V, Vetrepharm, IM) was administered and we performed OPU 22–24 h later for collection of MII

oocytes. OPU was performed three times in the same animals at intervals of approximately 80 days between the synchronizations.

#### **Oocytes selection criteria**

During the three collections for each group, we selected only those follicles with diameter greater than 8 mm for OPU. Cumulus–oocyte complexes collected at GV stage were used for *in vitro* maturation if the oocyte presented homogeneous cytoplasm and at least two compact layers of cumulus cells. Cumulus–oocyte complexes collected at MII phase were used for further procedures if the oocyte presented homogeneous cytoplasm and several layers of expanded cumulus cells.

The procedures involving animal handling were approved by the Ethics Committee of the University of São Paulo – School of Animal Sciences and Food Engineering.

#### In vitro maturation of GV oocytes

Oocytes collected at GV phase were matured *in vitro* for 22 h in TCM-199 medium (Sigma) supplemented with 10% bovine fetal serum (Sigma), 5.0  $\mu$ g/ml LH, 0.5  $\mu$ g/ml FSH, 200  $\mu$ M pyruvate (Sigma), and 50  $\mu$ g/ml gentamicin (Sigma). *In vitro* maturation culture was carried out in 100  $\mu$ l droplets (20–25 oocytes in each droplet) under mineral oil at 38.5°C and an atmosphere of 5% CO<sub>2</sub> in air.

#### **RNA** extraction and amplification

For each of the three replicates, we selected 50 in vitromatured and 50 in vivo-matured oocytes presenting the first polar body after removal of cumulus cells. The oocytes were pooled and stored at -80°C in calciumand magnesium-free phosphate-buffered saline (PBS) with 0.1% polyvinyl alcohol (PVA) and 100 U/ml RNase inhibitor (Invitrogen). RNA extraction from oocytes was performed using RNeasy Protect Mini Kit (Qiagen) following the manufacturer's recommendations. Total RNA (~10 ng) was used as template for mRNA amplification with the SuperScript RNA Amplification Kit (Invitrogen) following the manufacturer's recommendations and  $oligo(dT)_{12-18}$  as primers. Samples of amplified mRNA (mRNAa) were assayed in a Bioanalyzer 2100 equipment to assess quality and integrity using the RNA 6000 LabChip kit, following the manufacturer's recommendations (Agilent Technologies).

#### Probe labelling and microarray hybridization

Hybridization probes from the mRNAa were prepared by reverse transcription followed by the incorporation of Cy3 or Cy5 fluorophores according to the recommendations of CyScribe Post-Labelling Kit and CyScribe GFX Purification (GE Healthcare). cDNA labelled with Cy3 or Cy5 was measured in a NanoDrop 2000 spectrophotometer. Hybridizations were performed on microarray slides (BLO Plus (GPL9176)), containing oligonucleotides (70-mer) representing 8400 bovine genes. This long oligo set includes 10 bovine control genes and 10 Stratagene Alien Genes spotted multiple times on the array. Approximately 400 ng of labelled cDNA was hybridized to the microarray, following the dye-swap schema with two technical replicates. Thus, for each of the three biological replicates, we hybridized four slides, composing 12 slides for the experiment. Hybridization was carried in an automated station (Tecan HS400) for 6 h at 42°C, for 6 h at 35°C and for 6 h at 30°C, followed by three washes in  $2 \times$  sodium chloride and sodium citrate (SSC), 1% sodium dodecyl sulfate (SDS) at 37°C, three washes in  $0.1 \times$  SSC, 0.1% SDS at 30°C and other three washes in  $0.1 \times$  SSC at 25°C.

#### Data collection and analysis

The array images were digitalized by GenePix 4000B (Axon Instruments). The images were compiled using Imagene 5.0 (BioDiscovery), followed by the identification of the points of fluorescence and by background reading.

Raw intensities were normalized by the Lowess local regression using the LIMMA computational package according to procedures recommended for dye-swap labelling (Smyth & Speed 2003; Smyth 2005). The data obtained from the array spots were filtered and processed in order to eliminate poor quality, saturated or low fluorescence intensity spots relative to the background. Following data normalization, spots with intensity two-fold or greater than the background were considered for downstream analysis. Student's t-test was used to assess the statistical significance between the gene expression data generated from two experimental groups. Genes were inferred as differentially expressed between in vivo- and in vitromatured oocytes if fold change was  $\geq 2$  and *P*-value < 0.05.

The list of differentially expressed genes (DEG) was queried for biological processes potentially affected by *in vitro* maturation of oocytes using DAVID Bioinformatics Resources (v6.7, (Huang *et al.*, 2009)). The probabilities of significance were adjusted for multiple hypotheses testing using false discovery rate (FDR) (Benjamini & Yekutieli 2001), and a Gene Ontology term was assumed enriched if FDR < 0.1. The DEGs were overplayed on the topology of a protein–protein network according to the human and mouse BioGRID (v.3.2) database (Chatr-Aryamontri *et al.*, 2013) The network was built by expanding one protein interaction from each gene. The putative protein–protein network with DEGs in oocytes was visualized in Cytoscape (Shannon *et al.*, 2003).

#### Validation of the microarray results

In order to validate the microarray, cDNA was synthesized from the mRNAa used for the preparation of probes. The nine genes with the greatest difference in expression between in vivoand in vitro-matured oocytes and known to be associated with the physiology of oocyte maturation were chosen for validation. Five of those genes were up-regulated (EZR, EPN1, PSEN2, FST, and IGFBP3), and four genes were down-regulated (RBBP4, STAT3, FDPS, IRS1) in in vivo-matured oocytes. Primers and probes for TaqMan Gene Expression Assays were designed by the manufacturer (Bt03223252\_m1), EPN1 (EZR (Bt03233436\_g1), PSEN2 (Bt03237484\_m1), FST (Bt03259671\_m1) and IGFBP3 (Bt03223808\_m1), RBBP4 (Bt03230465\_g1), STAT3 (Bt03259866\_g1), FDPS (Bt03216346 g1), Applied Biosystems). The exception was *IRS1* primers (GGCAGATCTGGATAATCGGT, whose AATGGAAGCCACAGAGGACT) and probe (CGG-ACTCACTCTGCGGGCAC) were made to order.

Reverse transcription was performed with the SuperScript II kit, following the manufacturer's recommendations (Invitrogen) and oligo(dT)<sub>12-18</sub> as primers. The real-time PCR reactions were set up according to the TaqMan PCR Master Mix Kit (Applied Biosystems). Real-time PCR data were normalized relative to H2A histone family gene, member Z (H2AFZ, Bower et al., 2007) and fold changes were calculated according to the  $2^{-\Delta\Delta CT}$  method (Livak & Schmittgen, 2001). We used the in vivo-matured oocytes as calibrator sample. The  $\Delta$ CTs were used as input for analysis of variance (BioEstats 5.0) (Ayres et al., 2007) to assess the significance of differential gene expression between the two groups (Yuan *et al.*, 2006). Differential gene expression between in vivoor in vitro-matured oocytes was assumed significant when P < 0.05.

### Results

# Genes expressed in bovine oocytes matured *in vivo* and *in vitro*

Our experiment yielded 1488 genes quantified with two-fold or greater intensity than the background. Among these, 51 genes were up-regulated ( $\geq$ 2-fold) in *in vivo*-matured oocytes compared with *in vitro* counterparts (Table 1). By comparison, 56 genes were

	Accession no.	Ratio (in vivo/in vitro)
	NM_174217.2	5.74
	NM_174098.3	4.59
	NM_001038670.1	4.51
	NM_001040526.1	4.12
	NM_203358.2	3.99
	XM_589347.6	3.95
	XM_002707780.2	3.88
	NM_001105433.1	3.84
	NM_001080316.2	3.77
pe	NM_001079632.1	3.70
osine k	NM_001034334.1	3.66
	NM_001075702.1	3.57
	XM_002695198.2	3.51
	NM_174788.4	3.46
	NM_001192796.1	3.33
	NM_001038173.2	3.32
510	NM_001035314.2	3.30
	NM_174440.4	3.28
кDa	NM_001077860.1	3.27
	NM_175801.3	3.25
	NM_001102028.2	3.21
	NM_001034445.1	3.15
	NM_174522.2	2.90
2	NM 001205582 1	2 78

Table 1 Genes up-regulated in in vivo-matured ooc

Gene

ezrin

Symbol

EZR

	LZK	ezim	INIVI_1/421/.2	5.74
$CFB$ complement factor B         NM_001040526.1         4.12 $GAP43$ growth associated protein 43         NM_203358.2         3.99 $ATHL1$ acid trehalase-like         NM_58347.6         3.95 $SMARCC1$ SWI/SNF, actin         NM_001080316.2         3.88 $COL13A1$ collagen, type XII, alpha 1         NM_001080316.2         3.77 $MMAB$ methylmalonic acidiuria cblB type         NM_00107502.1         3.70 $LCK$ lymphocyte-specific protein tyrosine k         NM_001075702.1         3.57 $SPHK2$ sphingosine kinase 2         NM_001075702.1         3.57 $SPHK2$ sphingosine kinase 2         NM_001075702.1         3.33 $PLK1$ polo-like kinase 1         NM_00103514.2         3.20 $PSEN2$ presentin 2         NM_107488.4         3.46 $DSEMA$ diacylglycerol kinase, alpha 80kDa         NM_001035314.2         3.20 $PSEN2$ presentin 2         NM_00100208.2         3.21 $DKA$ diacylglycerol kinase, alpha 80kDa         NM_00103445.1         3.15 $OCKA$ diacylglycerol kinase, alpha 80kDa         NM_00103052.1<	LAP3	leucine aminopeptidase 3	NM_174098.3	4.59
$CFB$ complement factor B         NM_001040526.1         4.12 $GAP43$ growth associated protein 43         NM_203358.2         3.99 $ATHL1$ acid trehalase-like         NM_58347.6         3.95 $SMARCC1$ SWI/SNF, actin         NM_001080316.2         3.88 $COL13A1$ collagen, type XII, alpha 1         NM_001080316.2         3.77 $MMAB$ methylmalonic acidiuria cblB type         NM_00107502.1         3.70 $LCK$ lymphocyte-specific protein tyrosine k         NM_001075702.1         3.57 $SPHK2$ sphingosine kinase 2         NM_001075702.1         3.57 $SPHK2$ sphingosine kinase 2         NM_001075702.1         3.33 $PLK1$ polo-like kinase 1         NM_00103514.2         3.20 $PSEN2$ presentin 2         NM_107488.4         3.46 $DSEMA$ diacylglycerol kinase, alpha 80kDa         NM_001035314.2         3.20 $PSEN2$ presentin 2         NM_00100208.2         3.21 $DKA$ diacylglycerol kinase, alpha 80kDa         NM_00103445.1         3.15 $OCKA$ diacylglycerol kinase, alpha 80kDa         NM_00103052.1<	EPN1		NM_001038670.1	4.51
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	CFB			4.12
ATHL1         acid trehalase-like         XM_S8947.6         395           SMARCC1         SWI/SNE acin         XM_002707780.2         388           COL13A1         colagen, type XIII, alpha 1         NM_001080316.2         3.77           MMAB         methylmalonic acidutry bype         NM_001080316.2         3.77           LCK         lymphocyte-specific protein tyrosine k         NM_001034334.1         3.66           AP2A2         adaptor-related protein 2, $\alpha$ 2         NM_001034334.1         3.66           AP2A2         adaptor-related protein 2, $\alpha$ 2         NM_001034334.1         3.66           AP2A2         adaptor-related protein 2, $\alpha$ 2         NM_001034334.1         3.66           AP2A1         adaptor-related protein 2, $\alpha$ 2         NM_001038173.2         3.32           RPL72         ribosomal protes 510         NM_001038173.2         3.30           PSEN2         presenilin 2         NM_174404.4         3.28           DGKA         diacylglycerol kinase, alpha 80kDa         NM_001030786.1         3.27           FST         folitistarin         NM_017580.1         3.25           PK36K2         phosphoinositide-3-kinase, R6         NM_00103052.1         2.76           OX6A         cicytochrome c oxidase sub. 6A2         NM_01010358				
$\begin{array}{llllllllllllllllllllllllllllllllllll$				
$COL13AL$ collagen, type XIII, alpha 1         NM_001105433.1         3.84           MED29         mediator complex subunit 29         NM_001080316.2         3.77           MMAB         methylmalonic aciduria cblB type         NM_001079632.1         3.70           LCK         lymphocyte-specific protein tyrosine k         NM_001079632.1         3.57           LCK         lymphocyte-specific protein tyrosine k         NM_001079702.1         3.57           SPHK2         sphingosine kinase 2         XM_002695198.2         3.51           RPLP2         ribosomal protein, large, P2         NM_174400.4         3.33           PKB3         EPH receptor B3         NM_001035314.2         3.30           PSEN2         presenilin 2         NM_174400.4         3.28           DGKA         diacylglycerol kinase, alpha 80kDa         NM_001027860.1         3.27           FST         folistatin         NM_175801.3         3.25           PIK3R6         phosphoinositide-3-kinase, R6         NM_001020582.1         2.78           OXAK         NAD kinase         NM_001038882.1         2.67           NUL1         dynein, light chain, LC8-type 1         NM_001038882.1         2.67           NUL11         dynen, light chain, LC8-type 1         NM_001038882.1 <td></td> <td></td> <td></td> <td></td>				
MED29         mediator complex subunit 29         NM_001080316.2 $3.77$ MMAB         methylmalonic aciduria cblB type         NM_001079632.1 $3.70$ LCK         lymphocyte-specific protein tyrosine k         NM_001075702.1 $3.57$ SPHK2         sphingosine kinase 2         NM_001075702.1 $3.57$ SPHK2         sphingosine kinase 2         NM_00102796.1 $3.33$ PLP2         ribosomal protein, large, P2         NM_174788.4 $3.46$ EPHB3         EPH receptor B3         NM_001035314.2 $3.32$ MRP510         mitochondrial ribosomal prot. S10         NM_00107560.1 $3.27$ PK3         plosphoinositide-3-kinase, R6         NM_00107560.1 $3.27$ PK366         phosphoinositide-3-kinase, R6         NM_0010282.2 $2.21$ NADK         NAD kinase         NM_00103901.1 $2.73$ PYS6KB2         ribosomal protein S6 K, 70kDa, 2         NM_00103901.1 $2.73$ PYML1         dynein, Light chain, LC8-type 1         NM_00103901.1 $2.73$ PYS6KB2         ribosomal protein S         NM_00103901.1 $2.73$ PYS6KB2         ribosomal protein S				
MMAB         methylmalonic aciduria obl type         NM_001079632.1 $3.70$ LCK         lymphocyte-specific protein tyrosine k         NM_001034334.1 $3.66$ AP2A2         adaptor-related protein 2, $\alpha$ 2         NM_001075702.1 $3.57$ SPHK2         sphingosine kinase 2         XM_002695198.2 $3.51$ RPLP2         ribosomal protein, large, P2         NM_174788.4 $3.46$ EPHB3         EPH receptor B3         NM_001038173.2 $3.32$ MRP570         mitochondrial ribosomal prot. S10         NM_00103514.2 $3.30$ PSEN2         presentiln 2         NM_174440.4 $3.28$ DGKA         diacylglycerol kinase, alpha 80kDa         NM_001027860.1 $3.27$ SIX         prosphoinositide-3-kinase, R6         NM_00102428.2 $3.21$ NADK         NAD kinase         NM_001034445.1 $3.15$ COX6A2         cytochrome coxidase sub. 6A2         NM_174742.2         2.90           PYNLL1         dynein, light chain, LC8-type 1         NM_001030901.1         2.73           ETFB         electron-transfer-flavoprotein, β         NM_00103772.2         2.50           NGFRAP1         nerve growth factor r				
LCK         lymphocyte-specific protein tyrosine k         NML 001034334.1         3.66           AP2A2         adaptor-related protein 2, e 2         NML 001075702.1         3.57           SPIHK2         sphingosine kinase 2         XML 002695198.2         3.51           RPLP2         ribosomal protein, large, P2         NML 174788.4         3.46           EPHB3         EPH receptor B3         NML 001038173.2         3.32           MRPS10         mitochondrial ribosomal prot. 510         NML 001035314.2         3.30           DSKA         diacylglycerol kinase, alpha 80kDa         NM_001077860.1         3.27           FST         follistatin         NM_175801.3         3.25           DKAA         NADK         NAD kinase         NM_001034455.1         3.15           COX6A2         cytochrome c oxidase sub. 6A2         NM_01010208.2         3.21           NADK         NAD kinase         NM_00103901.1         2.73           DYNLL1         dynein, light chain, LC8-type 1         NM_001038582.1         2.66           ADIPOQ         adiponectin, C1Q collagen         NM_010103352         2.47           TLTB         electron-transfer-flavoprotein 1         NM_00110337.2         2.50           TACC3         transforming growth factor b         <				
$AP2A2$ adaptor-related protein 2, $\alpha 2$ NM_001075702.1         3.57 $SPHK2$ sphingosine kinase 2         XM_002695198.2         3.51 $SPHK2$ ribosomal protein, large, P2         NM_174788.4         3.46 $EPHB3$ $EPH$ receptor B3         NM_001192796.1         3.33 $PLK1$ polo-like kinase 1         NM_001035314.2         3.30 $PSEN2$ presenilin 2         NM_174440.4         3.28 $DGKA$ diacylglycerol kinase, alpha 80kDa         NM_001035314.2         3.20 $PK3R6$ phosphoinositide-3-kinase, R6         NM_00100208.2         3.21 $NADK$ NAD kinase         NM_01102028.2         3.21 $NADK$ NAD kinase         NM_001030541.1         2.78 $OYNLL1$ dynein, light chain, LC8-type 1         NM_00103901.1         2.73 $PTFSCAP$ protein tyrosine phosphatase         NM_001038582.1         2.67 $NULMA1$ nuclear mitotic apparatus protein 1         NM_001036582.1         2.66 $DIPOQ$ adiponectin C3 ecoled-coil         NM_001046618.1         2.50 $NGFRAP1$ nerve growth factor receptor         NM_0				
SPHK2         sphingosine kinase 2         XM_002695198.2         3.51           RPLP2         ribosomal protein, large, P.2         NM_174788.4         3.46           EPHB3         EPH receptor B3         NM_001038173.2         3.32           MRP510         mitochondrial ribosomal prot. S10         NM_001038173.2         3.32           MRP510         mitochondrial ribosomal prot. S10         NM_0101038173.2         3.32           DGKA         diacylglycerol kinase, alpha 80kDa         NM_01010028.2         3.21           DKA         diacylglycerol kinase, alpha 80kDa         NM_0010028.2         3.21           NADK         NAD kinase         NM_0010028.2         3.21           NADK         NAD kinase         NM_001002582.1         2.78           DYNL11         dynein, light chain, LC8-type 1         NM_00103901.1         2.73           ETFB         electron-transfer-flavoprotein, $\beta$ NM_001030582.1         2.67           NUMA1         nuclear mitotic apparatus protein 1         NM_001035852.1         2.66           DFRCAP         protein tryrosine phosphatase         NM_001103051.2         2.47           IGFBP5         IGF-binding protein 5         NM_001103052.2         2.47           IGFBP5         IGF-binding protein 5         NM_				
RPLP2         ribosomal protein, large, P2         NM_174788.4         3.46           EPHB3         EPH receptor B3         NM_001192796.1         3.33           MRPS10         mitochondrial ribosomal prot. S10         NM_001035173.2         3.30           DRSN2         presentiln 2         NM_174440.4         3.28           DCKA         diacylglycerol kinase, alpha 80kDa         NM_010077860.1         3.27           FST         follistatin         NM_175801.3         3.25           PIK3R6         phosphoinositide-3-kinase, R6         NM_001034445.1         3.15           COX6A2         cytochrome c oxidase sub. 6A2         NM_174522.2         2.90           RPS6KB2         ribosomal protein 56 K, 70kDa, 2         NM_001003901.1         2.73           ETFB         electron-transfer-flavoprotein, $\beta$ NM_001038582.1         2.67           NUMA1         nuclear mitotic apparatus protein 1         NM_001038582.1         2.66           PTPRCAP         protein tyrosine phosphatase         NM_00103875.2         2.47           LTBP3         latent transforming growth factor b         NM_001192770.1         2.37           PTRCAP         protein 5         NM_001192703.1         2.47           LTBP3         latent transforming growth factor b				
EPHB3         EPH receptor B3         NM_001192796.1         3.33           PLK1         polo-like kinase 1         NM_001038173.2         3.32           MRP510         mitochondrial ribosomal prot. S10         NM_0101383714.2         3.30           PSEN2         presenilin 2         NM_17440.4         3.28           DGKA         diacylglycerol kinase, alpha 80kDa         NM_001077860.1         3.27           FST         follistatin         NM_175801.3         3.25           PIK3R6         phosphoinositide-3-kinase, R6         NM_00103282.2         3.21           NADK         NAD kinase         NM_174522.2         2.90           RP56K82         ribosomal protein 56 K, 70kDa, 2         NM_001025582.1         2.78           DYNLL1         dynein, light chain, LC8-type 1         NM_00103901.1         2.73           ETFB         electron-transfer-flavoprotein, $\beta$ NM_001039746.1         2.66           ADIPOQ         adiponectin, C1Q collagen         NM_174742.2         2.63           PTRCAP         protein trosine phosphatase         NM_001103052.2         2.47           LTBP3         latent transforming growth factor b         NM_001103032.2         2.47           LTBP3         latent transforming growth factor b         NM_0011037459.2<				
PLK1         polo-like kinase 1         NM_001035311.2         3.32           MRP510         mitochondrial ribosomal prot. S10         NM_001035314.2         3.30           PSEN2         presenilin 2         NM_174440.4         3.28           DGKA         diacylglycerol kinase, alpha 80kDa         NM_001077860.1         3.27           FST         follistatin         NM_174440.4         3.28           PK3R6         phosphoinositide-3-kinase, R6         NM_00102028.2         3.21           NADK         NAD kinase         NM_01034445.1         3.15           COX6A2         cytochrome c oxidase sub. 6A2         NM_010205582.1         2.78           DYNLL1         dynein, light chain, LC8-type 1         NM_00103901.1         2.73           ETFB         electron-transfer-flavoprotein, β         NM_001205746.1         2.66           ADIPOQ         adiponectin, C1Q collagen         NM_174742.2         2.63           PTRKCAP         protein tyrosine phosphatase         NM_001103052.2         2.47           LTBP3         latent transforming growth factor b         NM_001103052.2         2.47           LTBP3         latent transforming growth factor b         NM_001103052.2         2.37           FACC3         transforming growth factor b         NM_0011				
MRPS10         mitochondrial ribosomal prot. S10         NM_001035314.2         3.30           PSEN2         presentiln 2         NM_17440.4         3.28           DCKA         diacylglycerol kinase, alpha 80kDa         NM_001077860.1         3.27           FST         follistatin         NM_175801.3         3.25           PIK3R6         phosphoinositide-3-kinase, R6         NM_00102028.2         3.21           NADK         NAD kinase         NM_01034445.1         3.15           COX6A2         cytochrome c oxidase sub. 6A2         NM_174522.2         2.90           RPS6KB2         ribosomal protein \$6 K, 70kDa, 2         NM_0010305882.1         2.67           DYNL11         dynein, light chain, LC8-type 1         NM_001038582.1         2.66           ADIPOQ         adiponectin, C1Q collagen         NM_174742.2         2.63           NGFRAP1         nerve growth factor receptor         NM_001163777.2         2.50           NGFRAP1         nerve growth factor receptor         NM_001103005.2         2.47           LTBP3         latent transforming growth factor b         NM_00103073.2         2.33           FGFPb5         IGF-binding protein 5         NM_00103093.2         2.35           UBE2B         ubiquitin-conjugating enzyme E2B         NM_				
PSEN2         presenilin 2         NM_174440.4         3.28           DGKA         diacylglycerol kinase, alpha 80kDa         NM_001077860.1         3.27           FST         follistatin         NM_175801.3         3.25           PIK3R6         phosphoinositide-3-kinase, R6         NM_001102028.2         3.21           NADK         NAD kinase         NM_001102028.2         3.21           NADK         NAD kinase         NM_00100391.1         2.73           COX6A2         cytochrome c oxidase sub. 6A2         NM_001003901.1         2.73           DYNLL1         dynein, light chain, LC8-type 1         NM_001039582.1         2.66           NUMA1         nuclear mitotic apparatus protein 1         NM_001205746.1         2.66           ADIPOQ         adiponectin, C1Q collagen         NM_174742.2         2.63           PTPRCAP         protein tyrosine phosphatase         NM_00100377.2         2.50           NGFRAP1         nerve growth factor receptor         NM_001102057.2         2.47           LTBP3         latent transforming growth factor b         NM_001103705.2         2.47           LTBP3         latent transforming growth factor b         NM_001192707.1         2.37           STARD13         StAR-related lipid transfer         NM_00103032.				
DGKA         diacylglycerol kinase, alpha 80kDa         NM_001077860.1         3.27           FST         follistatin         NM_178801.3         3.25           PIK3R6         phosphoinositide-3-kinase, R6         NM_001102028.2         3.21           NADK         NAD kinase         NM_001034445.1         3.15           COX6A2         cytochrome c oxidase sub. 6A2         NM_174522.2         2.90           RPS6KB2         ribosomal protein S6 K, 70kDa, 2         NM_001003901.1         2.73           ETFB         electron-transfer-flavoprotein, β         NM_001003901.1         2.73           DYNLL1         dynencin, ClQ collagen         NM_174742.2         2.63           PTPRCAP         protein tyrosine phosphatase         NM_001103052.2         2.47           ADIPOQ         adiponectin, ClQ collagen         NM_001103052.2         2.47           ITBP3         latent transforming growth factor b         NM_001103052.2         2.47           ILTBP3         latent transforming growth factor b         NM_001103052.2         2.37           FSLD1         fibronectin type III and SPRY domain         NM_00103093.2         2.35           UBE2B         ubiquitin-conjugating enzyme E2B         NM_001037459.2         2.30           FSD1         fibronectin type II				
FSTfollistatinNM_175801.3 $3.25$ PIK3R6phosphoinositide-3-kinase, R6NM_00110228.2 $3.21$ NADKNAD kinaseNM_001034445.1 $3.15$ COX6A2cytochrome c oxidase sub. 6A2NM_00103901.1 $2.73$ PR56KB2ribosomal protein S6 K, 70kDa, 2NM_00103901.1 $2.73$ ETFBelectron-transfer-flavoprotein, $\beta$ NM_00103901.1 $2.73$ ETFBelectron-transfer-flavoprotein, $\beta$ NM_00103901.1 $2.67$ NUIMA1nuclear mitotic apparatus protein 1NM_00103582.1 $2.66$ ADIPOQadiponectin, C1Q collagenNM_174742.2 $2.63$ PTRCAPprotein tyrosine phosphataseNM_00116618.1 $2.50$ NGFRAP1nerve growth factor receptorNM_00110305.2 $2.47$ ITBP3latent transforming growth factor bNM_00110305.2 $2.37$ POLR2Epolymerase (RNA) II, 25kDaNM_0011920738.1 $2.37$ POLR2Epolymerase (RNA) II, 25kDaNM_00103759.2 $2.30$ FSD1fibronectin type III and SPRY domainNM_001037459.2 $2.30$ FSD1fibronectin type III and SPRY domainNM_001192715.1 $2.25$ PLOD3procellagen-lysine, 2-oxoglutarateNM_00119255.1 $2.20$ GFBP3IGF-binding protein 3NM_174556.1 $2.20$ GFD23glucose 6 phosphatase, catalytic, 3NM_181364.3 $2.20$ KEAP1kelch-like ECH-associated protein 1NM_001075826.1 $2.12$ MT66myogenic factor 6 (herculin)NM_181811.1				
PIK3R6phosphoinositide-3-kinase, R6NM_001102028.2 $3.21$ NADKNAD kinaseNM_01034445.1 $3.15$ COX6A2cytochrome c oxidase sub. $6A2$ NM_174522.2 $2.90$ RPS6KB2ribosomal protein S6 K, 70kDa, 2NM_001205582.1 $2.78$ DYNLL1dynein, light chain, LC8-type 1NM_00103901.1 $2.73$ ETFBelectron-transfer-flavoprotein, $\beta$ NM_001205746.1 $2.66$ ADIPOQadiponectin, C1Q collagenNM_174742.2 $2.63$ PTRCAPprotein tyrosine phosphataseNM_001163777.2 $2.50$ NGFRAP1nerve growth factor receptorNM_00110305.2 $2.47$ LTBP3latent transforming acidic coiled-coilNM_00110305.2 $2.47$ LTBP3latent transforming growth factor bNM_00110327.2 $2.37$ STARD13StAR-related lipid transferNM_00110327.2 $2.35$ UBE2Bubiquitin-conjugating enzyme E2BNM_001037459.2 $2.30$ FSD1fibronectin type III and SPRY domainNM_001037459.2 $2.30$ FDD1craniofacial development protein 1NM_174266.1 $2.26$ PHF19PHD finger protein 3NM_17456.1 $2.20$ GGPC3glucose 6 phosphatase, catalytic, 3NM_18131.1 $2.15$ FLAD3procollagen-lysine, 2-oxoglutarateNM_001013755.1 $2.21$ IGFBP3IGF-binding protein 3NM_17456.1 $2.20$ GGPC3glucose 6 (horculin)NM_181811.1 $2.15$ FLAD3serine threonine kinase, 39NM_001037607.1<		, , , ,		
NADKNAD kinaseNM_001034445.13.15 $COX6A2$ cytochrome c oxidase sub. $6A2$ NM_174522.22.90 $RP56KB2$ ribosomal protein 56 K, 70kDa, 2NM_001205582.12.78 $DYNLL1$ dynein, light chain, LC8-type 1NM_001003901.12.73 $ETFB$ electron-transfer-flavoprotein, $\beta$ NM_001038582.12.67 $NULMA1$ nuclear mitotic apparatus protein 1NM_010205746.12.66 $ADIPOQ$ adiponectin, C1Q collagenNM_174742.22.63 $PTPRCAP$ protein tyrosine phosphataseNM_001046618.12.50 $NGFRAP1$ nerve growth factor receptorNM_001163777.22.50 $TACC3$ transforming, acidic coiled-coilNM_00110305.22.47 $LTBP3$ latent transforming growth factor bNM_0011030745.22.37 $FARD13$ StAR-related lipid transferNM_001192070.12.37 $POLR2E$ polymerase (RNA) II, 25kDaNM_001038093.22.30 $FSD1$ fibronectin type III and SPRY domainNM_001037459.22.30 $FSD1$ fibronectin type III and SPRY domainNM_001193275.12.26 $PHF19$ PHD finger protein 1NM_174268.12.26 $PHF19$ PHD finger protein 3NM_101193275.12.21 $G6PC3$ glucose 6 phosphatase, catalytic, 3NM_18364.32.20 $GFPC3$ glucose 6 phosphatase, catalytic, 3NM_18364.32.20 $FKAP1$ kelch-like ECH-associated protein 1NM_0010175826.12.12 $AFFP1$ kelch-like ECH-associated prote				
$COX6A2$ cytochrome c oxidase sub. $6A2$ $NM_174522.2$ $2.90$ $RPS6KB2$ ribosomal protein $56$ K, $70kDa$ , $2$ $NM_001205582.1$ $2.78$ $DYNLL1$ dynein, light chain, LC8-type 1 $NM_001003901.1$ $2.73$ $ETFB$ electron-transfer-flavoprotein, $\beta$ $NM_001038582.1$ $2.67$ $NUMA1$ nuclear mitotic apparatus protein 1 $NM_001025746.1$ $2.66$ $ADIPOQ$ adiponectin, C1Q collagen $NM_174742.2$ $2.63$ $PTPRCAP$ protein tyrosine phosphatase $NM_001103757.2$ $2.50$ $NGFRAP1$ nerve growth factor receptor $NM_00110305.2$ $2.47$ $LTBP3$ latent transforming, acidic coiled-coil $NM_00110305.2$ $2.47$ $LTBP3$ latent transforming growth factor b $NM_00110305.2$ $2.37$ $POLR2E$ polymerase (RNA) II, 25kDa $NM_001192070.1$ $2.37$ $POLR2E$ polymerase (RNA) II, 25kDa $NM_001037459.2$ $2.30$ $FSD1$ fibronectin type III and SPRY domain $NM_00119275.1$ $2.25$ $PLDP1$ craniofacial development protein 1 $NM_174566.1$ $2.20$ $GFPC3$ glucose 6 phosphatase, catalytic, 3 $NM_174556.1$ $2.20$ $GFPC3$ glucose 6 phosphatase, catalytic, 3 $NM_183364.3$ $2.20$ $KEAP1$ kelch-like ECH-associated protein 1 $NM_00101037607.1$ $2.16$ $MYF6$ myogenic factor 6 (herculin) $NM_181811.1$ $2.15$ $STK39$ serine threonine kinase 39 $NM_001037607.1$ $2.11$ $MPR5$ WD repeat doma		1 1		
RPS6KB2ribosomal protein S6 K, 70kDa, 2NM_001205582.12.78DYNLL1dynein, light chain, LC8-type 1NM_00103901.12.73ETFBelectron-transfer-flavoprotein, $\beta$ NM_001038582.12.67NUIMA1nuclear mitotic apparatus protein 1NM_001205746.12.66ADIPOQadiponectin, C1Q collagenNM_174742.22.63PTPRCAPprotein tyrosine phosphataseNM_001103075.22.47ILTBP3latent transforming, acidic coiled-coilNM_00110305.22.47ILTBP3latent transforming growth factor bNM_00110305.22.47IGFBP5IGF-binding protein 5NM_001103035.22.35TARD13StAR-related lipid transferNM_001192738.12.37POLR2Epolymerase (RNA) II, 25kDaNM_001037459.22.30FSD1fibronectin type III and SPRY domainNM_001037459.22.30FSD1fibronectin type III and SPRY domainNM_001192715.12.25PLOD3procollagen-lysine, 2-oxoglutarateNM_001192355.12.21IGFBP3IGF-binding protein 3NM_174556.12.20G6PC3glucose 6 phosphatase, catalytic, 3NM_18364.32.20KEAP1kelch-like ECH-associated protein 1NM_0010037607.12.16MYF6myogenic factor 6 (herculin)NM_181811.12.15STK39serine threonine kinase 39NM_001037607.12.11WDR5WD repeat domain 5NM_001037675.22.11MDF5WD repeat domain 5NM_001037675.22.11<				
DYNLL1dynein, light chain, LC8-type 1NM_001003901.12.73ETFBelectron-transfer-flavoprotein, $\beta$ NM_001038582.12.67NUMA1nuclear mitotic apparatus protein 1NM_001205746.12.66ADIPOQadiponectin, C1Q collagenNM_174742.22.63PTPRCAPprotein tyrosine phosphataseNM_001163777.22.50NGFRAP1nerve growth factor receptorNM_001103052.22.47LTBP3latent transforming, acidic coiled-coilNM_001103052.22.47LTBP3latent transforming growth factor bNM_001192738.12.47IGFBP5IGF-binding protein 5NM_00119270.12.37POLR2Epolymerase (RNA) II, 25kDaNM_001037459.22.30FSD1fibronectin type III and SPRY domainNM_001081518.12.30CFDP1craniofacial development protein 1NM_174268.12.26PHF19PHD finger protein 19NM_001192715.12.25PLOD3procollagen-lysine, 2-oxoglutarateNM_001193255.12.21IGFBP3IGF-binding protein 3NM_174556.12.20G6PC3glucose 6 phosphatase, catalytic, 3NM_188364.32.20KEAP1kelch-like ECH-associated protein 1NM_001075826.12.12MYF6myogenic factor 6 (herculin)NM_181811.12.15STK39serime threonine kinase 39NM_001075826.12.12ARFP71ADP-ribosylation factor relatedNM_00103767.22.11WDR5WD repeat domain 5NM_00119372.12.05 <td></td> <td>-</td> <td></td> <td></td>		-		
ETFBelectron-transfer-flavoprotein, βNM_001038582.12.67NUMA1nuclear mitotic apparatus protein 1NM_001205746.12.66ADIPOQadiponectin, C1Q collagenNM_174742.22.63PTPRCAPprotein tyrosine phosphataseNM_00106618.12.50NGFRAP1nerve growth factor receptorNM_00110305.22.47LTBP3latent transforming, acidic coiled-coilNM_00110305.22.47LTBP3latent transforming growth factor bNM_001192738.12.47IGFBP5IGF-binding protein 5NM_001105327.22.37STARD13StAR-related lipid transferNM_001038093.22.35UBE2Bubiquitin-conjugating enzyme E2BNM_001037459.22.30CFDP1craniofacial development protein 1NM_174268.12.26PHF19PHD finger protein 19NM_001192715.12.25PLOD3procollagen-lysine, 2-oxoglutarateNM_00119255.12.20G6PC3glucose 6 phosphatase, catalytic, 3NM_174556.12.20GFPA1kelch-like ECH-associated protein 1NM_0010075826.12.12ITGA11integrin, alpha 11XM_002690525.22.16MYF6myogenic factor 6 (herculin)NM_181811.12.15STK39serine threonine kinase 39NM_001105475.22.11ARFRP1ADP-ribosylation factor relatedNM_001105475.22.11MD55WD repeat domain 5NM_001105475.22.11SAP30-likeSAP30-likeNM_001105475.22.11POLRMT <td></td> <td></td> <td></td> <td></td>				
NUMA1nuclear mitotic apparatus protein 1NM_001205746.12.66ADIPOQadiponectin, C1Q collagenNM_174742.22.63PTPRCAPprotein tyrosine phosphataseNM_001046618.12.50NGFRAP1nerve growth factor receptorNM_00110377.22.50TACC3transforming, acidic coiled-coilNM_00110305.22.47LTBP3latent transforming growth factor bNM_0011092738.12.47IGFbp5IGF-binding protein 5NM_001192070.12.37STARD13StAR-related lipid transferNM_001037459.22.30POLR2Epolymerase (RNA) II, 25kDaNM_001037459.22.30FSD1fibronectin type III and SPRY domainNM_001081518.12.30CFDP1craniofacial development protein 1NM_174268.12.26PHF19PHD finger protein 3NM_101193255.12.21IGFBP3IGF-binding protein 3NM_174566.12.20G6PC3glucose 6 phosphatase, catalytic, 3NM_18364.32.20KEAP1kelch-like ECH-associated protein 1NM_0010075826.12.12MYF6myogenic factor 6 (herculin)NM_001037607.12.11MYF6myogenic factor 6 (herculin)NM_001037652.22.16MYF5WD repeat domain 5NM_001105475.22.11SAP30-likeSAP30-likeNM_001191372.12.05POLRMTpolymerase (RNA) mitochondrialNM_001205551.12.04				
$ADIPOQ$ adiponectin, C1Q collagenNM_174742.22.63 $PTPRCAP$ protein tyrosine phosphataseNM_001046618.12.50 $NGFRAP1$ nerve growth factor receptorNM_001163777.22.50 $TACC3$ transforming, acidic coiled-coilNM_00110305.22.47 $LTBP3$ latent transforming growth factor bNM_001192738.12.47 $IGFB75$ $IGF-binding protein 5$ NM_001192738.12.47 $IGFB75$ $IGF-binding protein 5$ NM_001192070.12.37 $POLR2E$ polymerase (RNA) II, 25kDaNM_001038093.22.35 $UBE2B$ ubiquitin-conjugating enzyme E2BNM_001037459.22.30 $FSD1$ fibronectin type III and SPRY domainNM_001192715.12.25 $PLOD3$ procollagen-lysine, 2-oxoglutarateNM_001193255.12.21 $IGFP3$ $IGF-binding protein 3$ NM_174566.12.20 $G6PC3$ glucose 6 phosphatase, catalytic, 3NM_183364.32.20 $KEAP1$ kelch-like ECH-associated protein 1NM_001101142.12.16 $ITGA11$ integrin, alpha 11XM_002690525.22.16 $MYF6$ myogenic factor 6 (herculin)NM_181811.12.15 $STK39$ serine threonine kinase 39NM_001105475.22.11 $ARFRP1$ ADP-ribosylation factor relatedNM_001037607.12.11 $WDR5$ WD repeat domain 5NM_001105475.22.11 $SAP30L$ SAP30-likeNMA) mitochondrialNM_001205551.12.04				
PTPRCAPprotein tyrosine phosphataseNM_001046618.12.50NGFRAP1nerve growth factor receptorNM_001163777.22.50TACC3transforming, acidic coiled-coilNM_00110305.22.47LTBP3latent transforming growth factor bNM_001192738.12.47IGFBP5IGF-binding protein 5NM_001192070.12.37STARD13StAR-related lipid transferNM_001192070.12.37POLR2Epolymerase (RNA) II, 25kDaNM_001038093.22.35UBE2Bubiquitin-conjugating enzyme E2BNM_001037459.22.30FSD1fibronectin type III and SPRY domainNM_001081518.12.30CFDP1craniofacial development protein 1NM_174268.12.26PHF19PHD finger protein 19NM_001192715.12.25PLOD3procollagen-lysine, 2-oxoglutarateNM_001193255.12.21IGFBP3IGF-binding protein 3NM_174556.12.20G6PC3glucose 6 phosphatase, catalytic, 3NM_183364.32.20KEAP1kelch-like ECH-associated protein 1NM_001101142.12.16ITGA11integrin, alpha 11XM_002690525.22.16MYF6myogenic factor 6 (herculin)NM_181811.12.15STK39serine threonine kinase 39NM_001105475.22.11ARFRP1ADP-ribosylation factor relatedNM_001015475.22.11SAP30LSAP30-likeNM_00119372.12.05POLRMTpolymerase (RNA) mitochondrialNM_001205551.12.04	NUMA1		NM_001205746.1	
NGFRAP1         nerve growth factor receptor         NM_001163777.2         2.50           TACC3         transforming, acidic coiled-coil         NM_001100305.2         2.47           LTBP3         latent transforming growth factor b         NM_001192738.1         2.47           IGFBP5         IGF-binding protein 5         NM_001105327.2         2.37           STARD13         StAR-related lipid transfer         NM_001103093.2         2.35           POLR2E         polymerase (RNA) II, 25kDa         NM_001037459.2         2.30           FSD1         fibronectin type III and SPRY domain         NM_001081518.1         2.30           FSD1         fibronectin type III and SPRY domain         NM_001192715.1         2.25           PLOD3         procollagen-lysine, 2-oxoglutarate         NM_001193255.1         2.21           IGFBP3         IGF-binding protein 3         NM_174556.1         2.20           G6PC3         glucose 6 phosphatase, catalytic, 3         NM_183364.3         2.20           KEAP1         kelch-like ECH-associated protein 1         NM_00101142.1         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1	-		NM_174742.2	
TACC3       transforming, acidic coiled-coil       NM_001100305.2       2.47         LTBP3       latent transforming growth factor b       NM_001192738.1       2.47         IGFBP5       IGF-binding protein 5       NM_001105327.2       2.37         STARD13       StAR-related lipid transfer       NM_001192070.1       2.37         POLR2E       polymerase (RNA) II, 25kDa       NM_001038093.2       2.35         UBE2B       ubiquitin-conjugating enzyme E2B       NM_001037459.2       2.30         FSD1       fibronectin type III and SPRY domain       NM_001081518.1       2.30         CFDP1       craniofacial development protein 1       NM_174268.1       2.26         PHF19       PHD finger protein 19       NM_001192715.1       2.25         PLOD3       procollagen-lysine, 2-oxoglutarate       NM_001193255.1       2.21         IGFBP3       IGF-binding protein 3       NM_174556.1       2.20         G6PC3       glucose 6 phosphatase, catalytic, 3       NM_183364.3       2.20         KEAP1       kelch-like ECH-associated protein 1       NM_001011142.1       2.16         MYF6       myogenic factor 6 (herculin)       NM_181811.1       2.15         STK39       serine threonine kinase 39       NM_001075826.1       2.12	PTPRCAP		NM_001046618.1	
LTBP3       latent transforming growth factor b       NM_001192738.1       2.47         IGFBP5       IGF-binding protein 5       NM_001105327.2       2.37         STARD13       StAR-related lipid transfer       NM_001192070.1       2.37         POLR2E       polymerase (RNA) II, 25kDa       NM_001038093.2       2.35         UBE2B       ubiquitin-conjugating enzyme E2B       NM_001037459.2       2.30         FSD1       fibronectin type III and SPRY domain       NM_010181518.1       2.30         CFDP1       craniofacial development protein 1       NM_01192715.1       2.26         PHF19       PHD finger protein 19       NM_001193255.1       2.21         IGFBP3       IGF-binding protein 3       NM_174556.1       2.20         G6PC3       glucose 6 phosphatase, catalytic, 3       NM_18364.3       2.20         KEAP1       kelch-like ECH-associated protein 1       NM_001101142.1       2.16         ITGA11       integrin, alpha 11       XM_002690525.2       2.16         MYF6       myogenic factor 6 (herculin)       NM_181811.1       2.15         STK39       serine threonine kinase 39       NM_001037607.1       2.11         WDR5       WD repeat domain 5       NM_001105475.2       2.11         SAP30L <t< td=""><td>NGFRAP1</td><td></td><td>NM_001163777.2</td><td>2.50</td></t<>	NGFRAP1		NM_001163777.2	2.50
IGFBP5       IGF-binding protein 5       NM_001105327.2       2.37         STARD13       StAR-related lipid transfer       NM_001192070.1       2.37         POLR2E       polymerase (RNA) II, 25kDa       NM_001038093.2       2.35         UBE2B       ubiquitin-conjugating enzyme E2B       NM_001037459.2       2.30         FSD1       fibronectin type III and SPRY domain       NM_001081518.1       2.30         CFDP1       craniofacial development protein 1       NM_174268.1       2.26         PHF19       PHD finger protein 19       NM_001192715.1       2.25         PLOD3       procollagen-lysine, 2-oxoglutarate       NM_001193255.1       2.21         IGFBP3       IGF-binding protein 3       NM_174556.1       2.20         G6PC3       glucose 6 phosphatase, catalytic, 3       NM_183364.3       2.20         KEAP1       kelch-like ECH-associated protein 1       NM_001101142.1       2.16         ITGA11       integrin, alpha 11       XM_002690525.2       2.16         MYF6       myogenic factor 6 (herculin)       NM_181811.1       2.15         STK39       serine threonine kinase 39       NM_001075826.1       2.12         ARFRP1       ADP-ribosylation factor related       NM_0011037607.1       2.11         WDR5 </td <td>TACC3</td> <td>transforming, acidic coiled-coil</td> <td>NM_001100305.2</td> <td>2.47</td>	TACC3	transforming, acidic coiled-coil	NM_001100305.2	2.47
STARD13       StAR-related lipid transfer       NM_001192070.1       2.37         POLR2E       polymerase (RNA) II, 25kDa       NM_001038093.2       2.35         UBE2B       ubiquitin-conjugating enzyme E2B       NM_001037459.2       2.30         FSD1       fibronectin type III and SPRY domain       NM_001081518.1       2.30         CFDP1       craniofacial development protein 1       NM_174268.1       2.26         PHF19       PHD finger protein 19       NM_001192715.1       2.25         PLOD3       procollagen-lysine, 2-oxoglutarate       NM_001193255.1       2.21         IGFBP3       IGF-binding protein 3       NM_174556.1       2.20         G6PC3       glucose 6 phosphatase, catalytic, 3       NM_183364.3       2.20         KEAP1       kelch-like ECH-associated protein 1       NM_001101142.1       2.16         ITGA11       integrin, alpha 11       XM_002690525.2       2.16         MYF6       myogenic factor 6 (herculin)       NM_181811.1       2.15         STK39       serine threonine kinase 39       NM_001037607.1       2.11         WDR5       WD repeat domain 5       NM_001105475.2       2.11         SAP30L       SAP30-like       NM_00110205551.1       2.04	LTBP3	latent transforming growth factor b	NM_001192738.1	2.47
POLR2E         polymerase (RNA) II, 25kDa         NM_001038093.2         2.35           UBE2B         ubiquitin-conjugating enzyme E2B         NM_001037459.2         2.30           FSD1         fibronectin type III and SPRY domain         NM_001081518.1         2.30           CFDP1         craniofacial development protein 1         NM_174268.1         2.26           PHF19         PHD finger protein 19         NM_001192715.1         2.25           PLOD3         procollagen-lysine, 2-oxoglutarate         NM_001193255.1         2.21           IGFBP3         IGF-binding protein 3         NM_174556.1         2.20           G6PC3         glucose 6 phosphatase, catalytic, 3         NM_183364.3         2.20           KEAP1         kelch-like ECH-associated protein 1         NM_0001101142.1         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_00119372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04	IGFBP5	IGF-binding protein 5	NM_001105327.2	2.37
POLR2E         polymerase (RNA) II, 25kDa         NM_001038093.2         2.35           UBE2B         ubiquitin-conjugating enzyme E2B         NM_001037459.2         2.30           FSD1         fibronectin type III and SPRY domain         NM_001081518.1         2.30           CFDP1         craniofacial development protein 1         NM_174268.1         2.26           PHF19         PHD finger protein 19         NM_001192715.1         2.25           PLOD3         procollagen-lysine, 2-oxoglutarate         NM_001193255.1         2.21           IGFBP3         IGF-binding protein 3         NM_174556.1         2.20           G6PC3         glucose 6 phosphatase, catalytic, 3         NM_183364.3         2.20           KEAP1         kelch-like ECH-associated protein 1         NM_0001101142.1         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_00119372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04	STARD13	StAR-related lipid transfer	NM_001192070.1	2.37
$UBE2B$ ubiquitin-conjugating enzyme E2BNM_001037459.22.30 $FSD1$ fibronectin type III and SPRY domainNM_001081518.12.30 $CFDP1$ craniofacial development protein 1NM_174268.12.26 $PHF19$ PHD finger protein 19NM_001192715.12.25 $PLOD3$ procollagen-lysine, 2-oxoglutarateNM_001193255.12.21 $IGFBP3$ IGF-binding protein 3NM_174556.12.20 $G6PC3$ glucose 6 phosphatase, catalytic, 3NM_183364.32.20 $KEAP1$ kelch-like ECH-associated protein 1NM_001101142.12.16 $ITGA11$ integrin, alpha 11XM_002690525.22.16 $MYF6$ myogenic factor 6 (herculin)NM_181811.12.15 $STK39$ serine threonine kinase 39NM_001037607.12.11 $WDR5$ WD repeat domain 5NM_001105475.22.11 $SAP30L$ SAP30-likeNM_001191372.12.05 $POLRMT$ polymerase (RNA) mitochondrialNM_001205551.12.04	POLR2E		NM_001038093.2	2.35
FSD1       fibronectin type III and SPRY domain       NM_001081518.1       2.30         CFDP1       craniofacial development protein 1       NM_174268.1       2.26         PHF19       PHD finger protein 19       NM_001192715.1       2.25         PLOD3       procollagen-lysine, 2-oxoglutarate       NM_01193255.1       2.21         IGFBP3       IGF-binding protein 3       NM_174556.1       2.20         G6PC3       glucose 6 phosphatase, catalytic, 3       NM_183364.3       2.20         KEAP1       kelch-like ECH-associated protein 1       NM_001101142.1       2.16         ITGA11       integrin, alpha 11       XM_002690525.2       2.16         MYF6       myogenic factor 6 (herculin)       NM_181811.1       2.15         STK39       serine threonine kinase 39       NM_0010037607.1       2.11         WDR5       WD repeat domain 5       NM_001105475.2       2.11         SAP30L       SAP30-like       NM_001191372.1       2.05         POLRMT       polymerase (RNA) mitochondrial       NM_001205551.1       2.04	UBE2B	ubiquitin-conjugating enzyme E2B	NM_001037459.2	2.30
CFDP1         craniofacial development protein 1         NM_174268.1         2.26           PHF19         PHD finger protein 19         NM_001192715.1         2.25           PLOD3         procollagen-lysine, 2-oxoglutarate         NM_001193255.1         2.21           IGFBP3         IGF-binding protein 3         NM_174556.1         2.20           G6PC3         glucose 6 phosphatase, catalytic, 3         NM_183364.3         2.20           KEAP1         kelch-like ECH-associated protein 1         NM_001101142.1         2.16           ITGA11         integrin, alpha 11         XM_002690525.2         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_0010075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001105475.2         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04	FSD1		NM_001081518.1	2.30
PHF19         PHD finger protein 19         NM_001192715.1         2.25           PLOD3         procollagen-lysine, 2-oxoglutarate         NM_001193255.1         2.21           IGFBP3         IGF-binding protein 3         NM_174556.1         2.20           G6PC3         glucose 6 phosphatase, catalytic, 3         NM_183364.3         2.20           KEAP1         kelch-like ECH-associated protein 1         NM_001101142.1         2.16           ITGA11         integrin, alpha 11         XM_002690525.2         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_0010075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001205551.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04	CFDP1		NM_174268.1	2.26
PLOD3         procollagen-lysine, 2-oxoglutarate         NM_001193255.1         2.21           IGFBP3         IGF-binding protein 3         NM_174556.1         2.20           G6PC3         glucose 6 phosphatase, catalytic, 3         NM_183364.3         2.20           KEAP1         kelch-like ECH-associated protein 1         NM_001101142.1         2.16           ITGA11         integrin, alpha 11         XM_002690525.2         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_0011037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04	PHF19		NM_001192715.1	2.25
IGFBP3       IGF-binding protein 3       NM_174556.1       2.20         G6PC3       glucose 6 phosphatase, catalytic, 3       NM_183364.3       2.20         KEAP1       kelch-like ECH-associated protein 1       NM_001101142.1       2.16         ITGA11       integrin, alpha 11       XM_002690525.2       2.16         MYF6       myogenic factor 6 (herculin)       NM_181811.1       2.15         STK39       serine threonine kinase 39       NM_001075826.1       2.12         ARFRP1       ADP-ribosylation factor related       NM_001037607.1       2.11         WDR5       WD repeat domain 5       NM_001105475.2       2.11         SAP30L       SAP30-like       NM_001191372.1       2.05         POLRMT       polymerase (RNA) mitochondrial       NM_001205551.1       2.04	PLOD3			2.21
G6PC3         glucose 6 phosphatase, catalytic, 3         NM_183364.3         2.20           KEAP1         kelch-like ECH-associated protein 1         NM_001101142.1         2.16           ITGA11         integrin, alpha 11         XM_002690525.2         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04	IGFBP3			2.20
KEAP1         kelch-like ECH-associated protein 1         NM_001101142.1         2.16           ITGA11         integrin, alpha 11         XM_002690525.2         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04				
ITGA11         integrin, alpha 11         XM_002690525.2         2.16           MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04				
MYF6         myogenic factor 6 (herculin)         NM_181811.1         2.15           STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04				
STK39         serine threonine kinase 39         NM_001075826.1         2.12           ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04				
ARFRP1         ADP-ribosylation factor related         NM_001037607.1         2.11           WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04				
WDR5         WD repeat domain 5         NM_001105475.2         2.11           SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04				
SAP30L         SAP30-like         NM_001191372.1         2.05           POLRMT         polymerase (RNA) mitochondrial         NM_001205551.1         2.04				
POLRMTpolymerase (RNA) mitochondrialNM_001205551.12.04		1		
<u></u>				
		510 with homone receptor	1111_1/0000.1	2.02


down-regulated ( $\geq$ 2-fold) in *in vivo*-matured oocytes (Table 2). Among these 107 DEGs genes, 25 genes were annotated to the enriched Gene Ontology (GO) biological process 'negative regulation of cellular process' (FDR < 0.1, Table 3). Noticeably, several of these 25 DEGs are also possibly associated with regulation of metabolic processes (FDR < 0.2, Table 3). Further inspection of these 25 DEGs demonstrated

Table 2 Genes down-regulated in in vivo-matured oocytes compared to in vitro counterparts

Symbol	Gene	Accession no.	Ratio (in vivo/in vitro)
IRS1	insulin receptor substrate-1	XM_003585773.2	0.17
H3F3A	H3 histone, family 3A	NM_001014389.2	0.20
SUCLG2	succinate-CoA ligase, GDP form	NM_001034639.1	0.21
CNOT7	CCR4-NOT transcription complex	NM_001034312.1	0.22
SUPT3H	suppressor of Ty 3 homolog	NM_001105008.1	0.22
RDH10	retinol dehydrogenase 10	NM_174734.2	0.23
CXCR5	chemokine C-X-C motif) R5	NM_001011675.1	0.24
RBBP7	retinoblastoma binding protein 7	NM_001034638.1	0.24
GOPC	Golgi associated PDZ and coiled-coil	NM_001206157.1	0.24
LGTN	ligatin	BT021884.1	0.25
BAZ1A	bromodomain adjacent to zinc finger	NM_001192940.1	0.25
RBBP4	retinoblastoma binding protein 4	NM_001077013.2	0.25
HMGB2	high-mobility group box 2	NM_001037616.1	0.26
HDAC2	histone deacetylase 2	NM_001075146.1	0.26
LRRC1	leucine rich repeat containing 1	NM_001205469.1	0.26
RBP4	retinol binding protein 4	NM_001040475.2	0.26
TMSB4X	thymosin beta 4, X-linked	NM_001002885.1	0.27
GBP5	guanylate binding protein 5	NM_001075746.1	0.27
TPX2	TPX2, microtubule-associated, targeting protein for Xklp2	NM_001098898.1	0.27
NDUFA1	NADH dehydrogenase 1 alpha	NM_175794.2	0.27
KIAA1310	KIAA1310 ortholog	NM_001099172.1	0.28
FLNC	filamin C, gamma	NM_001206990.1	0.28
STAT3	transducer and activator of transcription	NM_001012671.2	0.28
CALML5	calmodulin-like	NM_001098049.2	0.28
LMAN1	lectin, mannose-binding, 1	NM_001098049.2	0.28
HSPA9	heat shock 70 protein 9 (mortalin)		0.28
KAT2A		NM_001034524.1	0.29
	K (lysine) acetyltransferase 2A	NM_021078.2	
HPRT1	hypoxanthine phosphoribosyltransferase	NM_001034035.2	0.31
DEF6	differentially expressed in FDCP 6	NM_001098994.1	0.32
YIF1A	Yip1 interacting factor homolog A	NM_001034269.2	0.32
RASA1	RAS p21 protein activator 1	NM_174449.2	0.32
SFT2D1	SFT2 domain containing 1	NM_001034551.1	0.35
SLC7A14	solute carrier family 7, n14	NM_001077992.2	0.35
MOBKL2A	MOB1, Binder kinase activator	BT021734.1	0.36
CCNB1	cyclin B1	NM_001045872.1	0.36
NR1H2	nuclear receptor subfamily 1, H2	NM_001014883.1	0.37
PATZ1	POZ and AT hook containing zinc	NM_001191197.1	0.37
SNRPF	small nuclear ribonucleoprotein F	NM_001195027.1	0.37
DEDD	death effector domain containing	NM_001034643.2	0.37
KNG1	kininogen 1	NM_175774.3	0.37
ATF2	activating transcription factor 2	NM_001081584.2	0.38
SLC34A2	solute carrier family 34, n2	NM_174661.2	0.38
SOX18	SRY sex region Y)-box 18	NM_001075789.1	0.40
SNRPE	small nuclear ribonucleoprotein E	NM_001083459.2	0.42
MID1	midline 1	NM_001192822.1	0.43
NCOA1	nuclear receptor coactivator 1	NM_001206215.1	0.43
IDUA	iduronidase, alpha-L	XM_002688446.2	0.43
CTNNB1	catenin beta 1	NM_001076141.1	0.44
FLRT3	fibronectin leucine rich transmembrane	NM_001192674.1	0.44
SEPHS1	selenophosphate synthetase 1	NM_001075316.1	0.45
TSSC1	Tumor suppressing subtransferable	NM_001191328.1	0.45
FDPS	farnesyl diphosphate synthase	NM_177497.2	0.46
GGT7	gamma-glutamyltransferase 7	NM_001076401.1	0.47
SLC2A8	solute carrier family 2 member 8	NM_201528.1	0.47
TMEM59L	transmembrane protein 59-like	NM_001075301.1	0.49
NPHP1	nephronophthisis 1	NM_001105332.1	0.49

Category	Term	P-value	FDR	Gene symbols
GO:0048513	Organ development	0.0003	0.0566	RBP4, HMGB2, FST, ITGA11, HPRT1, CTNNB1, EZR, CXCR5, PATZ1, SOX18, CALML5, RASA1, IDUA, GHR, MYF6, SPHK2, COL13A1, TACC3, IRS1, STAT3, CCNB1, SMARCC1, LCK, PSEN2, GAP43, IGFBP5
GO:0048523	Negative regulation of cellular process	0.0003	0.0566	RBP4, HMGB2, DEDD, FST, CTNNB1, NR1H2, DYNLL1, GOPC, RASA1, HSPA9, MYF6, KNG1, RBBP4, SPHK2, RBBP7, MID1, IRS1, ADIPOQ, STAT3, HDAC2, PSEN2, CFDP1, TMSB4X, IGFBP3, IGFBP5
GO:0031324	Negative regulation of cellular metabolic process	0.0014	0.1280	MYF6, HMGB2, DEDD, FST, RBBP7, ADIPOQ, STAT3, CTNNB1, NR1H2, HDAC2, DYNLL1, PSEN2, IGFBP3, IGFBP5
GO:0009892	Negative regulation of metabolic process	0.0029	0.1280	MYF6, HMGB2, DEDD, FST, RBBP7, ADIPOQ, STAT3, CTNNB1, NR1H2, HDAC2, DYNLL1, PSEN2, IGFBP3, IGFBP5
GO:0031325	Positive regulation of cellular metabolic process	0.0030	0.1280	MYF6, HMGB2, HPRT1, CNOT7, ADIPOQ, IRS1, STAT3, CTNNB1, NR1H2, CCNB1, NCOA1, HDAC2, PLK1, SMARCC1, GHR
GO:0048522	Positive regulation of cellular process	0.0035	0.1280	MYF6, KNG1, RBP4, HMGB2, SPHK2, DEDD, CNOT7, HPRT1, ADIPOQ, IRS1, STAT3, CTNNB1, NR1H2, CCNB1, NCOA1, HDAC2, DYNLL1, PLK1, SMARCC1, LCK, PSEN2, NGFRAP1, IGFBP3, GHR
GO:0043434	Response to peptide hormone stimulus	0.0044	0.1280	SLC2A8, RBP4, UBE2B, IRS1, STAT3, GHR
GO:0045185	Maintenance of protein location	0.0045	0.1280	EZR, GOPC, TMSB4X, TACC3
GO:0009893	Positive regulation of metabolic process	0.0046	0.1280	MYF6, HMGB2, HPRT1, CNOT7, ADIPOQ, IRS1, STAT3, CTNNB1, NR1H2, CCNB1, NCOA1, HDAC2, PLK1, SMARCC1, GHR
GO:0031323	Regulation of cellular metabolic process	0.0047	0.1280	SUPT3H, HMGB2, DEDD, FST, KEAP1, HPRT1, CNOT7, ATF2, CTNNB1, DGKA, NR1H2, DYNLL1, MED29, PATZ1, SOX18, SAP30L, RASA1, GHR, KAT2A, MYF6, RBBP4, SPHK2, RBBP7, IRS1, ADIPOQ, STAT3, CCNB1, NCOA1, PHF19, BAZ1A, HDAC2, PLK1, SMARCC1, PSEN2, IGFBP3, GAP43, IGFBP5

Table 3 Top 10 GO biological processes associated with DEG between *in vivo-* and *in vitro-*matured oocytes



**Figure 1** Regulatory protein–protein network of genes affected by the *in vitro* culture of oocytes. (*A*) Genes up-regulated in *in vivo*-matured (MII) oocytes collected *in vivo*. (*B*) Genes down-regulated in MII oocytes collected *in vivo*. Differentially expressed genes (DEGs) are marked in red or blue, and yellow depicts the proteins potentially interacted with DEGs. The insets highlight the direct connection between proteins whose coding genes are differentially regulated by *in vitro* maturation.

that nine of them are involved in regulation of transcription (*CTNNB1*, *DEDD*, *FST*, *HMGB2*, *HDAC2*, *MYF6*, *NR1H2*, *RBBP7*, *STAT3*).


Next, we searched for altered gene expression that would affect interacting proteins. Most DEGs were part of a protein-protein network. Forty out of 51 genes up-regulated in *in vivo*-matured oocytes composed a protein interaction network (Fig. 1A), four of those genes identified two pairs of direct protein-protein interaction (Fig. 1A, inset). Two of those genes are associated with the transcription complex, namely: polymerase (RNA) II (DNA directed) polypeptide A and the Mediator Complex Subunit 29. By comparison, 41 of the 56 genes up-regulated in in vitro-matured oocytes composed another protein-protein network (Fig. 1B), 10 of which identified direct protein interactions (Fig.  $1B_{t}$ , inset). It is noteworthy that we found four genes associated with chromatin remodelling factors that were positively modulated by *in vitro* culture, namely: H3 histone, family3A, retinoblastoma binding protein 4 and 7, and bromodomain adjacent to zinc finger domain, 1A.

# Confirmation of differentially expressed genes by real-time PCR

We used real-time PCR to validate our microarray results. The nine genes tested were differentially expressed in *in vivo*-matured oocytes (*EZR*, *EPN1*, *IRS1*, *FDPS*, *FST*, *IGFBP3*, *PSEN2*, *RBBP4*, *STAT3*) compared with *in vitro*-matured oocytes in the two analyses, microarray and RT-PCR (P < 0.05. Fig. 2).

## Discussion

We determined whether the *in vitro* maturation process affected the gene expression of oocytes collected from *Bos taurus indicus* cows. With our investigation, we showed that 107 genes have altered expression due to the *in vitro* maturation system. Functional annotation of the data suggests that dysfunctional gene expression is not random and mostly affected the metabolism of oocytes. Inspection of the GO annotation of the genes suggests that one of the metabolic processes highly affected is the regulation of RNA synthesis.



**Figure 2** Relative expression of transcripts in *in vivo*- and *in vitro*-matured oocytes. Significant differences (P < 0.05) between groups (*in vivo* versus *in vitro*) are denoted by an asterisk. The results of three replicates are shown.

Corroborating our results, 21 of the DEGs were previously shown to be associated with oocyte developmental competence, 13 of those genes were up-regulated in *in vivo*-matured oocytes (DGKA (Beltman et al., 2010), GHR (Caixeta et al., 2009), FST (Bonnet et al., 2011), HMGB2 (Corcoran et al., 2007), TACC3 (Hao et al., 2002), IGFBP3 (Sawai 2009), EZR (Heng et al., 2011), KEAP1 (Powell et al., 2010), SMARCC1 (Lisboa et al., 2012), PLK1 (Sun et al., 2012), NGFRAP1 (Jiang et al., 2010), NUMA (Kolano et al., 2012) and EPN1 (Liu & Zheng, 2009)) and eight of them were up-regulated in in vitro-matured oocytes [IRS-1 (Yamamoto-Honda et al., 1996), STAT3 (Mohammadi-Sangcheshmeh et al., 2011), CCNB1 (Liu et al., 2012), RBBP4 and RBBP7 (Gasca et al., 2008), *ATF2* (Vigneault *et al.*, 2009), *TPX2* (Brunet *et al.*, 2008) and HDAC2 (Caixeta et al., 2013)]. This observation supports our approach and analysis. Most importantly, we showed 86 new potential biomarkers associated with oocyte competence. Further investigation will be required to conclusively demonstrate that the transcription of these 86 genes are specifically altered in oocytes collected from *B. taurus indicus* and matured in vitro.

Functional analysis of the DEGs revealed that 37 genes were annotated to 'regulation of cellular metabolic process', which was previously shown to be important for the maturation of oocytes (Fair *et al.*, 2007; Katz-Jaffe *et al.*, 2009). Interestingly, 26 (of the 37) DEGs were also functionally related to 'negative regulation of cellular process', and those genes are potentially important for cytoplasmic maturation (Ferreira *et al.*, 2009), and developmental potential of the oocytes. The dysregulation of a metabolic process such as the synthesis of RNA, due to *in vitro* maturation, is likely to affect the transcription during cleavage stages of development (Smith *et al.*, 2009) and alter cleavage kinetics during embryo development (Knijn *et al.*, 2003).

Our results of the transcriptome analysis were further supported by protein–protein interactome. The formation of protein-protein networks composed of the majority of genes either up-regulated (Fig. 1A) or down-regulated (Fig. 1B) regulated in in vivomatured oocytes strongly suggests biological coregulation of such genes in MII oocytes. Interestingly, we observed subsets of DEGs whose protein may form regulatory complexes (Fig. 1, insets). Two examples of gene co-expression and protein-protein interaction are potentially associated with gene regulation. First, the transcripts of MED29 and POLR2E are up-regulated in *in vivo*-matured oocytes, where this protein complex may function in the elongation phase of transcription (Takahashi *et al.*, 2011). Second, we found the complex formed around the retinoblastoma binding protein 4 (RBBP4) in the genes up-regulated in *in vitro*-matured oocytes. The abnormal abundance of this complex may contribute to negative regulation of genes important for embryo development (Wolffe et al., 2000). These results showed that the in vitro culture system also disturbs the regulation of oocyte's gene expression at the transcriptional level.

In summary, we established the transcript profile of *in vivo*- and *in vitro*-matured oocytes of *Bos taurus indicus* cows using microarray technology. Our experiment allowed us to uncover genes potentially involved in the control of oocyte competence. In light of our results, we suggest that the harmonious function of metabolism and regulation of gene expression is pivotal for the acquisition of oocyte developmental competence. The identification of potential competence markers will be useful for developing better *in vitro* culture conditions to allow the oocyte to adequately obtain competence.

## Acknowledgements

We thank Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 05/58702–4 and 05/59694-5) and Universidade de São Paulo (USP/FZEA) for financially supporting the project.

### References

- Ayres, M., Ayres, J.M., Ayres, D.L. & Santos, A.S. (2007). BioEstat 5.0. Statistical Applications in Biological and Medical Sciences. Sociedade Civil Mamirauá, Brasília, CNPq, 138 pp.
- Belli, M., Cimadomo, D., Merico, V., Redi, C.A., Garagna, S. & Zuccotti, M. (2013). The NOBOX protein becomes undetectable in developmentally competent antral and ovulated oocytes. *Int. J. Dev. Biol.* 57, 35–9.
- Beltman, M.E., Forde, N., Furney, P., Carter, F., Roche, J.F., Lonergan, P. & Crowe, M.A. (2010). Characterisation of endometrial gene expression and metabolic parameters in beef heifers yielding viable or non-viable embryos on day 7 after insemination. *Reprod. Fertil. Dev.* 22, 987–99.
- Benjamini, Y. & Yekutieli, D. (2001). The control of the false discovery rate in multiple testing under dependency. *Annals Stat.* 29, 1165–88.
- Bessa, I.R., Nishimura, R.C., Franco, M.M. & Dode, M.A.N. (2013). Transcription profile of candidate genes for the acquisition of competence during oocyte growth in cattle. *Reprod. Domest. Anim.* 48, 781–9.
- Biase, F.H., Fonseca Merighe, G.K., Santos-Biase, W., Martelli, L. & Meirelles, F.V. (2008). Global poly(A) mRNA expression profile measured in individual bovine oocytes and cleavage embryos. *Zygote* 16, 29–38.
- Biase, F.H., Martelli, L., Puga, R., Giuliatti, S., Santos-Biase, W.K., Fonseca Merighe, G.K. & Meirelles, F.V. (2010). Messenger RNA expression of *Pabpnl1* and *Mbd3l2* genes in oocytes and cleavage embryos. *Fertil. Steril.* **93**, 2507–12.
- Biase, F.H., Everts, R.E., Oliveira, R., Santos-Biase, W.K., Fonseca Merighe, G.K., Smith, L.C., Martelli, L., Lewin, H. & Meirelles, F.V. (2014). Messenger RNAs in metaphase II oocytes correlate with successful embryo development to the blastocyst stage. *Zygote* 22, 69–79.
- Bonnet, A., Bevilacqua, C., Benne, F., Bodin, L., Cotinot, C., Liaubet, L., Sancristobal, M., Sarry, J., Terenina, E. & Martin, P. (2011). Transcriptome profiling of sheep granulosa cells and oocytes during early follicular development obtained by laser capture microdissection. *BMC Genomics* 12, 417.
- Bower, N.I., Moser, R.J., Hill, J.R., Lehnert, S.A. (2007). Universal reference method for real-time PCR gene expression analysis of preimplantation embryos. *Biotechniques* 42, 199–206.
- Brunet, S., Dumont, J., Lee, K.W., Kinoshita, K., Hikal, P., Gruss, O.J., Maro, B. & Verlhac, M.-H. (2008). Meiotic regulation of TPX2 protein levels governs cell cycle progression in mouse oocytes. *PLoS One* 3, e3338.

- Caixeta, E.S., Ripamonte, P., Franco, M.M., Junior, J.B. & Dode, M.A.N. (2009). Effect of follicle size on mRNA expression in cumulus cells and oocytes of *Bos indicus*: an approach to identify marker genes for developmental competence. *Reprod. Fertil. Dev.* **21**, 655–64.
- Caixeta, E.S., Sutton-McDowall, M.L., Gilchrist, R.B., Thompson, J.G., Price, C.A., Machado, M.F., Lima, P.F. & Buratini, J. (2013). Bone morphogenetic protein 15 and fibroblast growth factor 10 enhance cumulus expansion, glucose uptake, and expression of genes in the ovulatory cascade during *in vitro* maturation of bovine cumulus–oocyte complexes. *Reproduction* **146**, 27–35.
- Chatr-Aryamontri, A., Breitkreutz, B.J., Heinicke, S., Boucher, L., Winter, A., Stark, C., Nixon, J., Ramage, L., Kolas, N., O'Donnell, L., Reguly, T., Breitkreutz, A., Sellam, A., Chen, D., Chang, C., Rust, J., Livstone, M., Oughtred, R., Dolinski, K. & Tyers, M. (2013). The BioGRID interaction database: 2013 update. *Nucleic Acids Res.* 41, D816–23.
- Corcoran, D., Rizos, D., Fair, T., Evans, A.C. & Lonergan, P. (2007). Temporal expression of transcripts related to embryo quality in bovine embryos cultured from the twocell to blastocyst stage *in vitro* or *in vivo*. *Mol. Reprod. Dev.* 74, 972–977.
- Fair, T., Carter, F., Park, S., Evans, A.C.O. & Lonergan, P. (2007). Global gene expression analysis during bovine oocyte *in vitro* maturation. *Theriogenology* 68, S91–7.
- Ferreira, E.M., Vireque, A.A., Adona, P.R., Meirelles, F.V., Ferriani, R.A. & Navarro, P.A.A.S. (2009). Cytoplasmic maturation of bovine oocytes: structural and biochemical modifications and acquisition of developmental competence. *Theriogenology* **71**, 836–48.
- Gandolfi, T.A. & Gandolfi, F. (2001). The maternal legacy to the embryo: cytoplasmic components and their effects on early development. *Theriogenology* **55**, 1255–76.
- Gasca, S., Pellestor, F., Assou, S., Loup, V., Anahory, T., Dechaud, H., De Vos, J. & Hamamah, S. (2008). Identifying new human oocyte marker genes: a microarray approach. *Reprod. Biomed. Online* **14**, 175–83.
- Hao, Z., Stoler, M.H., Sen, B., Shore, A., Westbrook, A., Flickinger, C.J., Herr, J.C. & Coonrod, S.A. (2002). TACC3 expression and localization in the murine egg and ovary. *Mol. Reprod. Dev.* 63, 291–9.
- Heng, S., Cervero, A., Simon, C., Stephens, A.N., Li, Y., Zhang, J., Paule, S., Rainczuk, A., Singh, H. & Quinonero, A. (2011). Proprotein convertase 5/6 is critical for embryo implantation in women: regulating receptivity by cleaving EBP50, modulating ezrin binding, and membrane-cytoskeletal interactions. *Endocrinology* 152, 5041–52.
- Huang, D.W., Sherman, B.T. & Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. *Nat. Protoc.* 4, 44– 57.
- Jiang, J.-Y., Xiong, H., Cao, M., Xia, X., Sirard, M.-A. & Tsang, B.K. (2010). Mural granulosa cell gene expression associated with oocyte developmental competence. *J. Ovarian Res.* **3**, 6.
- Kanka, J., Nemcova, L., Toralova, T., Vodickova-Kepkova,K., Vodicka, P., Jeseta, M. & Machatkova, M. (2012).Association of the transcription profile of bovine oocytes

and embryos with developmental potential. *Anim. Reprod. Sci.* **134**, 29–35.

- Katz-Jaffe, M.G., McCallie, B.R., Preis, K.A., Filipovits, J. & Gardner, D.K. (2009). Transcriptome analysis of *in vivo* and *in vitro* matured bovine MII oocytes. *Theriogenology* 71, 939–46.
- Knijn, H.M., Gjørret, J.O., Vos, P.L., Hendriksen, P.J., van der Weijden, B.C., Maddox-Hyttel, P. & Dieleman, S.J. (2003). Consequences of *in vivo* development and subsequent culture on apoptosis, cell number, and blastocyst formation in bovine embryos. *Biol. Reprod.* 69, 1371–8.
- Kolano, A., Brunet, S., Silk, A.D., Cleveland, D.W. & Verlhac, M.-H. (2012). Error-prone mammalian female meiosis from silencing the spindle assembly checkpoint without normal interkinetochore tension. *Proc. Natl. Acad. Sci.* 109, E1858–67.
- Labrecque, R., Vigneault, C., Blondin, P. & Sirard, M.A. (2013). Gene expression analysis of bovine oocytes with high developmental competence obtained from FSHstimulated animals. *Mol. Reprod. Dev.* 80, 428–40.
- Li, Y., Ray, D. & Ye, P. (2013). Identification of germ cellspecific genes in mammalian meiotic prophase. *BMC Bioinform.* 14, 1–13.
- Lisboa, L.A., Bordignon, V. & Seneda, M.M. (2012). Immunolocalization of BRG1–SWI/SNF protein during folliculogenesis in the porcine ovary. *Zygote* 20, 243–8.
- Liu, Z. & Zheng, Y. (2009). A requirement for epsin in mitotic membrane and spindle organization. J. Cell Biol. 186, 473– 80.
- Liu, W., Yin, J., Zhao, G., Yun, Y., Wu, S., Jones, K.T. & Lei, A. (2012). Differential regulation of cyclin B1 degradation between the first and second meiotic divisions of bovine oocytes. *Theriogenology* 78, 1171–81.
- Livak, K.J. & Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta CT}$  method. *Methods* **25**, 402–8.
- Mohammadi-Sangcheshmeh, A., Held, E., Ghanem, N., Rings, F., Salilew-Wondim, D., Tesfaye, D., Sieme, H., Schellander, K. & Hoelker, M. (2011). G6PDH-activity in equine oocytes correlates with morphology, expression of candidate genes for viability, and preimplantative *in vitro* development. *Theriogenology* **76**, 1215–26.
- Niemann, H., Carnwath, J.W. & Kues, W. (2007). Application of DNA array technology to mammalian embryos. *Theriogenology* 68, S165–77.
- Pocar, P., Brevini, T.A.L., Perazzoli, F., Cillo, F., Modina, S. & Gandolfi, F. (2001). Cellular and molecular mechanisms mediating the effects of polychlorinated biphenyls on oocyte developmental competence in cattle. *Mol. Reprod. Dev.* 60, 535–41.
- Powell, M.D., Manandhar, G., Spate, L., Sutovsky, M., Zimmerman, S., Sachdev, S.C., Hannink, M., Prather, R.S. & Sutovsky, P. (2010). Discovery of putative oocyte quality markers by comparative ExacTag proteomics. *PROTEOMICS – Clinical Applications* 4, 337–51.

- Sawai, K. (2009). Studies on gene expression in bovine embryos derived from somatic cell nuclear transfer. J. *Reprod. Dev.* 55, 11–6.
- Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B. & Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* 13, 2498–504.
- Sirard, M.-A., Richard, F., Blondin, P. & Robert, C. (2006). Contribution of the oocyte to embryo quality. *Theriogenology* 65, 126–36.
- Smith, S.L., Everts, R.E., Sung, L.Y., Du, F., Page, R.L., Henderson, B., Rodriguez-Zas, S.L., Nedambale, T.L., Renard, J.P., Lewin, H.A., Yang, X., Tian, X.C. (2009). Gene expression profiling of single bovine embryos uncovers significant effects of *in vitro* maturation, fertilization and culture. *Mol. Reprod. Dev.* **76**, 38–47.
- Smyth, G.K. (2005). Limma: linear models for microarray data. In *Bioinformatics and computational biology solutions using R and Bioconductor* (R. Gentleman, V. Carey, W. Huber, R. Irizarry & S. Dudoit, eds), pp. 397–420. Springer.
- Smyth, G.K. & Speed, T. (2003). Normalization of cDNA microarray data. *Methods* 31, 265–273.
- Sun, S.-C., Liu, H.-L. & Sun, Q.-Y. (2012). Survivin regulates Plk1 localization to kinetochore in mouse oocyte meiosis. *Biochem. Biophys. Res. Commun.* 421, 797–800.
- Takahashi, H., Parmely, T.J., Sato, S., Tomomori-Sato, C., Banks, C.A., Kong, S.E., Szutorisz, H., Swanson, S.K., Martin-Brown, S., Washburn, M.P., Florens, L., Seidel, C.W., Lin, C., Smith, E.R., Shilatifard, A., Conaway, R.C. & Conaway, J.W. (2011). Human mediator subunit MED26 functions as a docking site for transcription elongation factors. *Cell* 146, 92–104.
- Tomek, W., Torner, H. & Kanitz, W. (2002). Comparative analysis of protein synthesis, transcription and cytoplasmic polyadenylation of mRNA during maturation of bovine oocytes *in vitro*. *Reprod. Domest. Anim.* **37**, 86–91.
- Vigneault, C., McGraw, S. & Sirard, M.-A. (2009). Spatiotemporal expression of transcriptional regulators in concert with the maternal-to-embryonic transition during bovine *in vitro* embryogenesis. *Reproduction* **137**, 13–21.
- Wolffe, A.P., Urnov, F.D. & Guschin, D. (2000). Co-repressor complexes and remodelling chromatin for repression. *Biochem. Soc. Trans.* 28, 379–86.
- Yamamoto-Honda, R., Honda, Z.I., Ueki, K., Tobe, K., Kaburagi, Y., Takahashi, Y., Tamemoto, H., Suzuki, T., Itoh, K. & Akanuma, Y. (1996). Mutant of insulin receptor substrate-1 incapable of activating phosphatidylinositol 3kinase did not mediate insulin-stimulated maturation of *Xenopus laevis* oocytes. J. Biol. Chem. 271, 28677–81.
- Yu, J., Hecht, N.B. & Schultz, R.M. (2002). RNA-binding properties and translation repression *in vitro* by germ cellspecific MSY2 protein. *Biol. Reprod.* 67, 1093–8.
- Yuan, J.S., Reed, A., Chen, F. & Stewart, C.N., Jr (2006). Statistical analysis of real-time PCR data. *BMC Bioinformatics* 7, 85.